NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma Inc (NASDAQ:XLRN) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.03. The biopharmaceutical company had revenue of $4.20 million for the quarter, compared to analyst estimates of $4.44 million. Acceleron Pharma had a negative return on equity of 30.79% and a negative net margin of 353.57%. The company's quarterly revenue was up 27.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.63) earnings per share. View Acceleron Pharma's Earnings History.

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Acceleron Pharma.

Acceleron Pharma will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

14 brokers have issued 12 month target prices for Acceleron Pharma's stock. Their forecasts range from $45.00 to $138.00. On average, they anticipate Acceleron Pharma's share price to reach $94.31 in the next year. This suggests a possible upside of 4.0% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

News headlines about XLRN stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Acceleron Pharma earned a news impact score of 2.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Acceleron Pharma.

Some companies that are related to Acceleron Pharma include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), bluebird bio (BLUE), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF) and Momenta Pharmaceuticals (MNTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Gilead Sciences (GILD), Incyte (INCY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), Intel (INTC), LogicBio Therapeutics (LOGC) and Bausch Health Companies (BHC).

Acceleron Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Farallon Capital Management LLC (3.77%), State Street Corp (2.75%), Westfield Capital Management Co. LP (2.17%), Janus Henderson Group PLC (2.14%) and Eagle Asset Management Inc. (1.72%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Sujay Kango. View Institutional Ownership Trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Sofinnova Investments Inc., Janus Henderson Group PLC, Credit Suisse AG, AXA, Westfield Capital Management Co. LP, Candriam Luxembourg S.C.A. and Alliancebernstein L.P.. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View Insider Buying and Selling for Acceleron Pharma.

XLRN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Great Lakes Advisors LLC, Aviva PLC, Artisan Partners Limited Partnership, State Street Corp, Cubist Systematic Strategies LLC and UBS Asset Management Americas Inc.. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $90.67.

Acceleron Pharma has a market capitalization of $4.81 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]